Category (and subcategories) | Example of a clinical rule | |
---|---|---|
1 | Overrules of alerts for very severe DDIs generated by the CDSS | Reduced effect of valproic acid by carbapenems leading to an increased risk of convulsions |
2 | Drugs with a restricted indication or dosing | Patient with high dose meropenem |
3 | Medication use potentially leading to biochemical changes | |
* Drug use in renal insufficiency | Patient with a CrCl < 30 ml/min and treated with metformin | |
* Drugs with high potential of QTc interval prolongation | Patient with a QTc > 450/470 ms and treated with haloperidol | |
* Drug use associated with hyperpotassemia | Patient with a K > 5.5 mmol/L and treated with an ACE inhibitor | |
* Drug use associated with hypopotassemia | Patient with a K < 3.5 mmol/L and treated with flucloxacillin without potassium supplementation | |
* Drug use associated with supratherapeutic INR | Patient with a supratherapeutic INR (INR > 4) and treated with a VKA | |
* Drug use associated with bone marrow suppression | Patient with an absolute neutrophil count < 1.5*109/L and treated with clozapine | |
4 | Potential sequential therapy for bio-equivalent drugs | Potential sequential therapy for levofloxacine |
5 | Others | Patient treated with non-crushable drugs administered through enteral feeding tube |